Idenix Announces Data Presentation at the 48th Annual Meeting of the European Association for the Study of the Liver (EASL)

Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX ), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it will present data on IDX719, the Company's pan-genotypic HCV NS5A inhibitor, at the 48^th Annual Meeting of the European Association for the Study of the Liver